Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

Health policy experts said it is still unclear how much prices will go down, which medicines will be impacted and whether the ...

The Lilly announcement will extend an agreement aimed at accelerating medicine development and bolstering the ...

Weight loss drugs and jabs have become more popular and a recent study looked at the effectiveness of two drugs ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

The findings come after reports of nasty side effects - including eye problems, infections and gastrointestinal disorders - ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

As global equity markets expand, two corporate heavyweights are emerging as serious contenders to reach $1 trillion in market ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

Trump shared the anecdote as he signed an order Monday intended to drastically reduce the price Americans pay for pharmaceutical products — without naming the friend he was talking about.